Analysts Offer Predictions for 89bio FY2025 Earnings

89bio, Inc. (NASDAQ:ETNB) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of 89bio in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($2.44) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $29.00 target price on the stock. The consensus estimate for 89bio’s current full-year earnings is ($3.22) per share.

ETNB has been the topic of a number of other research reports. Raymond James raised 89bio to a “strong-buy” rating in a research report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of 89bio in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of 89bio in a research note on Saturday, January 18th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.33.

89bio Price Performance

Shares of NASDAQ ETNB opened at $6.92 on Thursday. The company has a current ratio of 11.66, a quick ratio of 11.66 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $7.80 and a two-hundred day simple moving average of $8.20. 89bio has a 1-year low of $5.99 and a 1-year high of $16.63. The firm has a market cap of $734.42 million, a price-to-earnings ratio of -2.38 and a beta of 1.14.

Hedge Funds Weigh In On 89bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ETNB. Janus Henderson Group PLC boosted its position in shares of 89bio by 14.2% during the 3rd quarter. Janus Henderson Group PLC now owns 15,158,218 shares of the company’s stock valued at $112,140,000 after acquiring an additional 1,882,108 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in 89bio in the third quarter valued at approximately $5,631,000. Westfield Capital Management Co. LP lifted its position in 89bio by 29.6% during the third quarter. Westfield Capital Management Co. LP now owns 3,006,038 shares of the company’s stock valued at $22,245,000 after purchasing an additional 686,673 shares during the last quarter. Walleye Capital LLC grew its stake in 89bio by 1,232.2% in the 3rd quarter. Walleye Capital LLC now owns 435,298 shares of the company’s stock worth $3,221,000 after buying an additional 402,624 shares in the last quarter. Finally, Exome Asset Management LLC bought a new position in shares of 89bio in the 3rd quarter worth $2,224,000.

Insider Activity

In other news, CEO Rohan Palekar purchased 5,000 shares of 89bio stock in a transaction dated Friday, December 6th. The stock was purchased at an average cost of $7.89 per share, for a total transaction of $39,450.00. Following the transaction, the chief executive officer now directly owns 471,236 shares of the company’s stock, valued at approximately $3,718,052.04. This trade represents a 1.07 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Charles Mcwherter purchased 10,000 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $80,000.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $80,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 30,000 shares of company stock worth $235,700 over the last ninety days. Company insiders own 2.80% of the company’s stock.

About 89bio

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.